antibiotic-impregnated catheter
DeviceHydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
NCT Number: NCT06276543
Research Purpose:
This study aims to continuously evaluate the safety of subjects implanted with a catheter (trade name: Bactiseal) produced by Integra LifeSciences Production Corporation. Device safety will be assessed based on all the adverse events that occurred within 2 years after implanted the catheter.
Research Design:
This study is designed to be single arm, multi-center, and retrospective. A total of 200 subjects will be retrospectively enrolled. Information will be collected on adverse events, including bacterial culture and drug resistance testing when infection (if done), of subjects enrolled within 2 years after the implantation of the Bactiseal Catheter between January 01, 2019 and June 30, 2022.
The following information will be collected from subjects' medical records or hospitals' databases (if any):
1. General condition of the subjects (including previous shunting and external drainage operation) 2. Intraoperative condition and catheter implantation 3. Information on the shunt catheters 4. Adverse events of subjects within 2 years after the operation and classification of the adverse events (except anticipated adverse events listed in section 8.1.2) 5. Relevant examinations in case of postoperative infection, including bacterial culture and drug resistance testing (if done)
Interested in participating?
Request InfoAll sexes
Observational
Beijing Hospital, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
Time frame: 2 years post catheter implanted.
Incidence of Bactiseal Shunt catheter related infection within 2 years post implant.
Time frame: 2 years post catheter implanted.
Incidence of adverse events of a subject within 2 years post implant Bactiseal
Contact information is provided by the study sponsor or research team.
Integra LifeSciences Corporation
Industry
A Multi-center, Retrospective Registry Study on the Safety of Bactiseal Catheter
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04496414
Brain Diseases, Central Nervous System Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07050628
Brain Diseases, Central Nervous System Diseases
Chicago, Illinois, United States
View Trial DetailsNCT06253858
Brain Diseases, Central Nervous System Diseases
Hershey, Pennsylvania, United States
View Trial DetailsNCT05910944
Brain Diseases, Central Nervous System Diseases
Kuopio, Finland
View Trial Details